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Recently the association between hepatic steatosis and sarcopenia has been described.
GH/IGF-1 axis has been postulated to play a role in linking fatty liver and low muscle mass.
The aim of our study was to explore the association between fatty liver index, sarcopenic
obesity, insulin sensitivity, and GH/IGF-1 status.
Methods
427 subjects [age: 45.65±13.94 years, BMI: 36.92±6.43 kg/m2] were enrolled. Participants
were divided into three groups: fatty liver index (FLI) <20, 20FLI<60, and FLI60. Body
composition was assessed by DXA. The truncal fat mass (TrFM) to appendicular skeletal
muscle (ASM) ratio was used as an indicator of sarcopenic obesity. ISI-Matsuda index was
used.
Results
BMI, fat mass, and the TrFM/ASM ratio were higher in subjects with FLI60. GH, IGF-1 and
ISI-Matsuda were lower in the high FLI group (all p<0.05). A significantly positive correlation
between FLI and TrFM/ ASM ratio (r = 0.221, p<0.001) was found, whereas FLI levels were
negatively correlated with ISI- Matsuda (r = -0.335, p<0.001), GH (r = -0.200, p = 0.006),
and IGF- 1 levels (r = -0.157, p = 0.028). Stepwise linear regression analysis showed that
GH levels were significantly negatively correlated with FLI, while the TrFM/ ASM ratio was
positively associated with FLI, after adjustment for age, BMI, total fat mass, truncal fat
mass, fat- free mass, and ISI- Matsuda.
Conclusions
Impairment of GH/IGF-1 axis seems to be associated to the risk of the development of sarco-
penic obesity and ectopic fat deposition in the liver. Metabolic and hormonal derangements
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Introduction
In the last decades, a growing body of evidence dealt with two important issues in the Western
world: sarcopenia and obesity, two faces of the challenge of healthy aging [1–3]. Moreover,
interest is mounting towards sarcopenic obesity, in which the two abovementioned conditions
coexist in a phenotype characterized by high adiposity and low lean body mass [3, 4].
Obesity is known to be strictly linked to fatty liver [5]. Recently, several studies reported an
association between low skeletal muscle mass and hepatic steatosis [6, 7]. Insulin resistance has
been demonstrated to occur in case of excess fat as well as in sarcopenia, given that skeletal
muscle is one of the major target tissues of insulin action [8, 9]. Anyway, the impairment of
insulin sensitivity may not be the only mediator of the development of fatty liver, and the role
of other potential contributors needs to be better clarified.
Growth hormone (GH) and insulin- like growth factor 1 (IGF- 1) exert significant effects on
body composition, and lipid and glucose homeostasis [10]. A wealth of studies reported that in
obese subjects GH secretion is blunted [10–12], and GH and IGF- 1 have been proven to be
involved in fatty infiltration of the liver [13, 14]. Likewise, ectopic fat deposition seems to be
linked to reduced GH levels [10, 15], as well as impairment in GH production occurring with
aging is one of the causes of the changes in body compartments leading to both excess adiposity
and sarcopenia [16].
More recently, GH has been postulated to play a role in the connection between nonalco-
holic fatty liver disease (NAFLD) and decline in muscle mass [17]. The aim of our study was to
investigate the association between fatty liver index, the phenotype of sarcopenic obesity, and
GH/ IGF- 1 status.
Materials and Methods
Study participants were recruited among subjects referring to the High Specialization Center
for the Care of Obesity at the Department of Experimental Medicine, “Sapienza” University of
Rome, Italy, from June 2011 to October 2014.
The inclusion criteria were: age between 18 and 65 years, diagnosis of obesity based on fat
mass> 25% in men and>35% in women [18], ethnicity: Caucasian Italian subjects. As exclu-
sion criteria, we considered: malignant disease during the last 5 years, inflammatory or autoim-
mune diseases, corticosteroids for systemic use, any medication or any clinical condition
potentially affecting body weight or body composition, syndromic obesity, participation in a
reducing-weight program in the last three months, renal failure, heart failure, any type of dia-
betes, history of viral or autoimmune liver disease or any other chronic liver disease, excessive
alcohol intake (> 140g/ week for men and 70g/ week for women).
The study protocol was approved by the Ethical Committee of the "Sapienza” University of
Rome, Italy, and the written informed consent was obtained from all the participants.
All subjects underwent a multidimensional evaluation, as follows.
Complete physical examination and anthropometric measurements. Body weight, height,
waist circumference were measured following the procedures described in the “Anthropomet-
ric standardization reference manual” [19]. An inter- assessor alignment training session pre-
ceded the measurements. The same tools were used in all subjects: a SECA scale 86 (200 kg, to
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the nearest 0.1 kg), a flexible metallic tape (200 cm, to the nearest 0.1 cm), a telescopic stadi-
ometer (200 cm; to the nearest 0.1 cm). Body mass index (BMI) was calculated as body weight
(kg) divided by height squared (m2).
Body composition analysis. Fat mass and fat- free mass were assessed by dual-energy-X-ray
absorptiometry (DXA) (Hologic 4500 RDR), with coefficient of variation of< 1.5% for fat
mass and fat- free mass. Segmental regions were also measured. Truncal fat mass (TrFM) was
assessed. Appendicular skeletal muscle mass (ASM) was evaluated by DXA and calculated as
the sum of lean soft tissue masses of arms and legs [20].
The ratio between truncal fat mass and appendicular skeletal muscle mass (TrFM/ ASM
ratio) was calculated and used as an index of sarcopenic obesity [21].
Biochemistry. Blood samples were collected after an overnight fast. The following biochemi-
cal parameters were assayed: fasting glucose and insulin, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), gamma- glutamyl transferase (GGT), triglycerides, GH and
IGF- 1, using commercial kits.
Glucose metabolism and insulin sensitivity. All participants underwent an oral glucose tol-
erance test (OGTT) for both glucose and insulin response. Insulin sensitivity was assessed as
the insulin sensitivity index (ISI) calculated using the OGTT values as proposed by Matsuda
and DeFronzo [22].
The fatty liver index (FLI) was calculated as follows [23]:
ðFLI ¼ ðe 0:953  loge ðtriglyceridesÞ þ 0:139  BMI þ 0:718
loge ðggtÞ þ 0:053  waist circumference  15:745Þ = ð1
þ e0:953  loge ðtriglyceridesÞ þ 0:139  BMI þ 0:718
loge ðggtÞ þ 0:053  waist circumference  15:745Þ  100Þ
Participants were divided into three groups, according to FLI values: FLI< 20, 20
FLI< 60, and FLI 60 [24].
Statistical analysis
After verification of normal data distribution, T- test was used to compare continuous vari-
ables, χ2 was applied to compare categorical variables. A univariate analysis was performed in
order to investigate the relationship among the outcome variable (FLI) and the independent
variables: GH, IGF- 1, TrFM/ ASM ratio for body composition, ISI- Matsuda for insulin sensi-
tivity (Pearson’s correlation coefficient). The predictors of the outcome variable, significantly
correlated at the univariate analysis, were included in a multiple linear regression model to ver-
ify the association among FLI and the independent variables.
The regression model was elaborated using a stepwise (cutoff for entry: 0.05, for removal:
0,10) procedure. The efficacy of the regression model was analyzed according to the value of
the determination coefficient R2 (comparing the explained variance of the model’s predictions
with the total variance of the data) and the R2 adjusted (considering a correction for inclusion
of variables). The standard error of the estimate (SEE), representing a measure of the accuracy
of predictions (standard deviation of the differences between the actual values of the dependent
variable and the predicted values), was calculated. A p value< 0.05 was considered statistically
significant.
Data were entered a Microsoft Excel database and analyzed using the statistical software
SPSS for Windows 10.0 (SPSS Inc. 1989–1999).
Fatty Liver Index, Sarcopenic Obesity and GH/ IGF-1 Axis
PLOS ONE | DOI:10.1371/journal.pone.0145811 January 7, 2016 3 / 9
Results
427 subjects (81 men and 346 women, mean age: 48.17 ± 14.84 and 45.06 ± 13.68 years, mean
BMI: 37.31 ± 6.40 and 36.83 ± 6.45 kg/m2, respectively) were enrolled. Only one man and 6
women presented a FLI value 20, thus we excluded them from the statistical analysis. The
intermediate and the high FLI groups were compared. Characteristics of study participants are
described in Table 1.
Age was not significantly different between the groups. BMI, waist circumference, absolute
body fat mass, body fat mass percentage, truncal fat mass, absolute fat- free mass, fat- free mass
percentage, appendicular skeletal muscle mass and the TrFM/ ASM ratio were significantly
higher in subjects with FLI 60, when compared with individuals in the intermediate FLI
group, regardless of gender. GH and IGF- 1 were significantly lower in subjects with FLI
values 60. Concerning insulin sensitivity, ISI- Matsuda was significantly reduced in the high
FLI group (all p values< 0.05).
A significantly positive correlation between FLI and TrFM/ ASM ratio (r = 0.221, p<0.001)
was observed (Table 2). On the contrary, FLI levels were negatively correlated with ISI- Mat-
suda (r = -0.335, p<0.001), GH (r = -0.200, p = 0.006), and IGF- 1 levels (r = -0.157, p = 0.028).
Stepwise linear regression analysis showed that GH levels were significantly negatively cor-
related with FLI, while the TrFM/ ASM ratio was positively associated with FLI, after adjust-
ment for age, BMI, total fat mass, truncal fat mass, fat- free mass, and ISI- Matsuda (Table 3).
Discussion
Separate associations between GH and IGF- 1 and hepatic steatosis, as well as connections
between GH pathway and metabolic response in adipose tissue and skeletal muscle are well
established. Only few studies described the association between sarcopenia and NAFLD [6,7].
However, the complex interplay between body composition, fatty infiltration of the liver, GH
status and insulin sensitivity has not been thoroughly investigated to date.
In the present study, we found a significant positive association between indices of fatty
liver and of sarcopenic obesity, and an inverse association between fatty liver index, sarcopenic
obesity phenotype, and GH status.
Consistent with previous studies, showing reduced levels of GH and IGF- 1 in case of
NAFLD [13,14] and obesity [10], our study population showed decreased circulating amounts
of GH and IGF- 1 in obese subjects with FLI values higher than 60. GH and IGF- 1 correlated
negatively and TrFM/ ASM ratio correlated positively with FLI in the univariate analysis. Body
size and body composition, especially fat mass, are known to influence individual components
of FLI (e.g. BMI and waist circumference) as well as GH status; on the other hand, insulin resis-
tance is notably linked to NAFLD. In the final model of multivariate regression, the positive
correlation of TrFM/ ASM ratio with FLI, and the negative correlation of GH with FLI as
dependent variable were maintained after adjusting the statistical model for other variables
potentially affecting this association, such as age, BMI, body composition (total fat mass, trun-
cal fat mass, fat- free mass) as well as ISI- Matsuda. Even though IGF- 1 is a mediator of GH
effects, it was excluded in the model because of collinearity [10, 16].
Our results seem to be in line with findings from Bredella et al. [25], showing an inverse
association between GH and intrahepatic lipid content in obese premenopausal women inde-
pendently of visceral fat and age. Similarly, in two other studies including Caucasian subjects
NAFLD detected by ultrasound was negatively associated with IGF- 1 levels after controlling
for BMI [26, 27], on the contrary, the strength of this relationship was attenuated when adjust-
ing for adiposity in the study by Runchey et al.[28], involving normal-weight- to- obese sub-
jects of mixed ethnicity.
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Consistent with data from the Korean Sarcopenic Obesity Study [7], showing a higher risk
of NAFLD in individuals with lower muscle mass after adjustment for HOMA- IR, we found a
significant inverse association between fatty liver index and the index of sarcopenic obesity
TrFM/ASM ratio after controlling for insulin resistance. In particular, we used the ISI- Mat-
suda that mirrors more exhaustively the impairment of insulin sensitivity [29]. Accordingly,
Table 1. Demographic, anthropometric andmetabolic characteristics of study participants (N = 420).
FLI 20–60 (N = 61) FLI > 60 (N = 359) p
Age (years) 42.69±14.48 46.20±13.80 0.058
BMI (Kg/m2) 29.59±2.22 38.29±6.02 <0.001
Waist circumference (cm)
M 97.50±4.09 122.11±11.96 0.001
F 98.07±7.02 118.61±12.01 <0.001
Fat mass (kg)
M 22.40±0.69 36.30±7.63 0.002
F 31.08±4.27 43.07±9.10 <0.001
Fat mass (%)
M 25.83±0.84 31.92±4.17 0.014
F 40.10±3.94 42.78±4.47 <0.001
Fat- free mass (kg)
M 59.52±4.10 72.82±10.09 0.014
F 44.36±5.70 53.53±8.13 <0.01
Fat- free mass (%)
M 74.17±0.84 68.03±4.17 0.013
F 59.91±3.94 57.22±4.47 <0.001
Truncal fat mass (kg)
M 11.11±1.12 19.14±4.34 0.002
F 13.81±2.21 20.63±4.69 <0.001
Truncal fat mass (%)
M 27.10±1.87 34.23±4.86 0.014
F 38.08±4.76 42.72±5.54 <0.001
ASM (kg)
M 26.23±2.41 32.22±4.78 0.035
F 18.88±2.88 23.04±3.95 <0.001
TrFM/ASM ratio
M 0.43±0.04 0.61±0.14 0.003
F 0.75±0.15 0.91±0.22 <0.001
GH (ug/mL) 2.08±0.79 0.92±0.74 0.008
IGF-1 (ng/mL) 216.80±85.29 176.08±92.63 0.031
ISI- Matsuda 5.03±3.14 3.03±2.27 <0.001
HbA1c (%) 5.36±0.44 5.97±1.12 <0.001
Triglycerides (mg/dL) 98.49±65.16 130.36±75.65 <0.001
AST (U/L) 17.51±4.99 22.78±12.70 <0.001
ALT (U/L) 19.39±8.11 30.43±21.92 <0.001
GGT (U/L) 16.74±10.07 28.93±23.56 <0.001
Legend: FLI = fatty liver index; BMI = body mass index; ASM = appendicular skeletal muscle; TrFM = truncal fat mass; GH = growth hormone; IGF-
1 = insulin- like growth factor 1; ISI = insulin sensitivity index; HbA1c = glycosylated haemoglobin; ALT = alanine aminotransferase, AST = aspartate
aminotransferase, GGT = gamma- glutamyl transferase.
doi:10.1371/journal.pone.0145811.t001
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various studies showed that insulin resistance is involved in the development of NAFLD and is
related to sarcopenia [9, 30, 31].
In line with previous data showing a poor control of glucose metabolism in subjects with
FLI 60 [6], our results suggest that in obese individuals in the high FLI group, the concomi-
tant presence of sarcopenia may worsen the negative metabolic effects of obesity on glucose
homeostasis.
As reported just by two other studies [6,7], we found a positive relationship between fatty
liver index and low relative skeletal muscle mass.
In our patients in the high FLI group, the absolute fat- free mass was increased. This observa-
tion may be explained by the fact that in obese subjects, in an adaptive mechanism counteract-
ing the increased load of fat mass, approximately 25% of the body mass consists of fat- free
tissues [32]. This homeostatic response may not be sufficient in functional and metabolic terms
in obese individuals leading to sarcopenic obesity [21]. Moreover, although not decreased, abso-
lute fat- free mass in our obese subjects was likely infiltrated by fat, as an inverse association
between GH status and thigh intramuscular fat was described [15]. Besides, according to others
[10, 33], the reduced GH and IGF- 1 levels seen in our population of obese patients, may be
detrimental both to liver and skeletal muscle, contributing to the ectopic fat storage. On the
basis of the above mentioned considerations, our findings are in line with the hypothesis raised
Table 2. Univariate correlation analysis among FLI and explanatory variables.
Variables r p
Age (years) 0.131 0.007
BMI (kg/m2) 0.691 <0.001
FM (kg) 0.586 <0.001
Truncal FM (kg) 0.662 <0.001
FFM (kg) 0.540 <0.001
TrFM/ ASM ratio 0.221 <0.001
GH (ug/mL) -0.200 0.006
IGF-1 (ng/mL) -0.157 0.028
ISI- Matsuda -0.335 <0.001
Legend: FLI = fatty liver index; TrFM/ ASM = truncal fat mass/ appendicular skeletal muscle; GH = growth
hormone; IGF- 1 = insulin- like growth factor 1; ISI = insulin sensitivity index
doi:10.1371/journal.pone.0145811.t002
Table 3. Stepwise linear regression analysis using FLI as dependent variable.
Model Unstandardized
Coefficients§
Standardized coefficients t p
B SE Beta
GH (ug/mL) -1.267 0.505 -0.133 -2.508 0.013
TrFM/ ASM ratio 25.095 5.953 0.271 4.215 <0.001
(Costant) -31.850 9.823 n. a. -3.242 0.002
R2 = 0.734; R2 adj. = 0.720; SEE = 11.13
§ After adjustment for age, BMI, total FM, FFM, truncal FM, and ISI- Matsuda
Legend: FLI = fatty liver index; GH = growth hormone; TrFM/ ASM = truncal fat mass/ appendicular skeletal muscle; SE = standard error; SEE = standard
error of the estimate; BMI = body mass index; FM = fat mass; FFM; = fat- free mass, ISI = insulin sensitivity index; n.a. = not available.
doi:10.1371/journal.pone.0145811.t003
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by Guichelaar and Charlton [17] suggesting GH status as a potential bridge between fatty liver
and sarcopenia.
A universally accepted definition of sarcopenic obesity is lacking to date. The majority of exist-
ing definitions of sarcopenic obesity relies on criteria considering sarcopenia and obesity sepa-
rately [4, 34]; most of these indices have been validated as opposed to functional impairment,
while just few recent studies focused on metabolic aspects [4, 34–37]. In the present study we
used the TrFM/ASM ratio to describe the sarcopenic obesity phenotype. This index, that includes
both fat mass and fat- free mass in a unique estimate, better captures the metabolic features due
to the disproportion in body compartments occurring in sarcopenic obesity [21]. In addition, we
defined obesity on the basis of the measured fat mass, a better criterion for the diagnosis of obesity
compared to an indirect index like BMI [18, 30].
Some limitations to our study need to be considered. Although the FLI has been validated
against hepatic ultrasonography and magnetic resonance spectroscopy [23, 38], it is a surrogate
marker of liver steatosis. Moreover, just a minority of obese subjects in our study population
had FLI values below 20. The stratification of FLI based on cut-off values seems not to be
completely appropriate for our cohort of obese subjects (mostly females), whose mean BMI
was higher than BMI in the validation study of FLI (largely males) [23], as well as in the study
by Gastaldelli and coll., using the same cut-off values than in our study [24]. In a recent study
by Cuthbertson and al. [38], FLI was linearly related to log- transformed liver fat assessed by
magnetic resonance spectroscopy, and was confirmed to be useful to identify subjects with
hepatic steatosis, even though it cannot be used to predict exactly the liver fat content. For
these reasons, we used FLI as a continuous variable in the regression analysis. Finally, our anal-
ysis does not prove a causal relationship among GH status, sarcopenic obesity and fatty liver.
The lack of a separate analysis of sarcopenic and nonsarcopenic obese subjects taking into
account sex hormones may represent another limitation to our study. Nevertheless, our study
population was composed mainly by adult subjects; evidence on changes in sex hormones and
body composition was provided especially by studies involving subjects in the menopausal
state and in the geriatric age (typically>65 years old). However, in the European Male Ageing
Study, no consistent association was observed between testosterone levels and change in mus-
cle mass, gait speed, or grip strength in middle-aged and elderly men [39].
In conclusion, our findings encompass previous evidence into a more comprehensive point
of view that relates metabolic and hormonal derangements as determinants of ectopic fat depo-
sition and body composition.
Obese subjects should be evaluated for metabolic features linked to fatty infiltration of liver
and muscle in particular. In addition, specific treatment strategies for the phenotype of sarco-
penic obesity should be adopted, to prevent detrimental changes in body composition due to
the altered GH/ IGF- 1 status.
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